SUNMONTUEWEDTHUFRISAT
Conferences, Lectures, & Seminars
Events for March
-
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Fri, Mar 07, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Aijun Wang, Ph.D. , ChancellorâÂÂs Fellow Professor of Surgery and Biomedical Engineering, Co-Director, Center for Surgical Bioengineering, Vice Chair for Translational Research, Innovation and Entrepreneurship, Department of Surgery UC Davis School of Medicine
Talk Title: "Engineering Stem Cells and Extracellular Components for In Utero Treatment of Congenital Anomalies"
Abstract: Birth defects contribute significantly to pediatric morbidity and mortality, affecting 1 in 33 infants in the United States. As the leading cause of infant mortality, many congenital anomalies lack effective treatments or cures. Emerging prenatal interventions – such as fetal surgery, in utero stem cell therapy and genome editing – offer the potential to treat or even cure these conditions before birth. Dr. Aijun Wang Lab at UC Davis is at the forefront of fetal tissue engineering and gene editing, developing innovative translational technologies to modify the fetal environment and address congenital disorders. The Wang lab develops innovative technologies for stem cell transplantation, and integrates stem cell-derived extracellular vesicles, biomaterial scaffolds mimicking the extracellular matrix, and non-viral gene editing techniques. A major focus of the lab has been pioneering stem cell therapy for in utero treatment of spina bifida. Their team successfully manufactured clinical-grade placenta-derived mesenchymal stem cells (PMSCs) at the UC Davis GMP facility, obtained FDA investigational new drug (IND) approval, and is currently conducting the world’s first stem cell clinical trial using PMSCs for prenatal spina bifida treatment. Additionally, the Wang Lab is advancing non-viral genome editing technologies using lipid nanoparticles to genetically correct developing stem cells, offering a potential prenatal treatment for genetic disorders. To enhance stem cell targeting and function, they have applied novel integrin-based ligands identified through One-Bead One-Compound (OBOC) combinatorial technology. These groundbreaking approaches mark a transformative step in prenatal medicine, with the potential to redefine the management of congenital anomalies.
Biography: Dr. Aijun Wang received his PhD in biology from Tsinghua University, Beijing, China and completed his postdoctoral training at University of California, Berkeley Bioengineering and Berkeley Stem Cell Center. He joined University of California, Davis (UC Davis) faculty in 2012, and is currently a Chancellor's Fellow Professor of Surgery and of Biomedical Engineering. He serves as Vice Chair for Translational Research, Innovation and Entrepreneurship in the Department of Surgery, Co-Director of the Center for Surgical Bioengineering, and inaugural Dean's Fellow in Entrepreneurship at the UC Davis School of Medicine. Additionally, he is a Principal Investigator at the Institute for Pediatric Regenerative Medicine (IPRM) / Shriners Children's Pediatric Research Center, Northern California. Dr. Wang’s research focuses on developing innovative tools, technologies, and therapeutics that integrate molecular, cellular, tissue, and biomaterial engineering to drive tissue regeneration and restore function. Dr. Wang’s lab utilizes single cell spatial multi-omics to study disease mechanisms and developmental process and engineers and develops stem cell therapy/genome editing, extracellular vesicles/nanomedicine, and extracellular matrix/biomaterial scaffolds to treat a wide spectrum of congenital conditions and acquired diseases. Dr. Wang specializes in translating discoveries from bench to bedside through innovative research, translational and investigational new drug (IND)-enabling studies, current Good Manufacturing Practice (cGMP) manufacturing, and clinical trials in both human and companion animal patients. Dr. Wang has published over 180 peer-reviewed papers in top-tier journals, such as Nature Nanotechnology, Nature Communications, ACS Nano, Advanced Functional Materials, Bioactive Materials, Biomaterials, Journal of Extracellular Vesicles, Stem Cells, and Theranostics. Since joining UC Davis, Dr. Wang has served as PI, MPI or Co-PI, on numerous major extramural and intramural grants, securing over $55 million in funding from agencies such as NIH/NINDS, NIH/NIBIB, NIH/NICHD, the California Institute for Regenerative Medicine (CIRM), the Tobacco-Related Disease Research Program of California (TRDRP), Shriners Hospital for Children, and other foundations. Dr. Wang has received numerous awards, such as the UC Davis Health Dean’s Fellowship (2018), the UC Davis Chancellor's Fellowship (2020), the UC Davis Health Dean’s Team Award for Excellence in Research (2020), the UC Davis School of Medicine Cultivating Team Science Award (2022), the KidneyX Innovation award (2020), and the Sacramento Region Innovation Award (2021). In recognition of his outstanding contributions to regenerative medicine and translational bioengineering, Dr. Wang was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2024.
Host: Eunji Chung
Location: Ronald Tutor Hall of Engineering (RTH) - Room 109
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor. -
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Fri, Mar 07, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Aijun Wang, Ph.D., ChancellorâÂÂs Fellow Professor of Surgery and Biomedical Engineering, Co-Director, Center for Surgical Bioengineering, Vice Chair for Translational Research, Innovation and Entrepreneurship, Department of Surgery UC Davis School of Medicine
Talk Title: Engineering Stem Cells and Extracellular Components for In Utero Treatment of Congenital Anomalies"
Abstract: Birth defects contribute significantly to pediatric morbidity and mortality, affecting 1 in 33 infants in the United States. As the leading cause of infant mortality, many congenital anomalies lack effective treatments or cures. Emerging prenatal interventions – such as fetal surgery, in utero stem cell therapy and genome editing – offer the potential to treat or even cure these conditions before birth. Dr. Aijun Wang Lab at UC Davis is at the forefront of fetal tissue engineering and gene editing, developing innovative translational technologies to modify the fetal environment and address congenital disorders. The Wang lab develops innovative technologies for stem cell transplantation, and integrates stem cell-derived extracellular vesicles, biomaterial scaffolds mimicking the extracellular matrix, and non-viral gene editing techniques. A major focus of the lab has been pioneering stem cell therapy for in utero treatment of spina bifida. Their team successfully manufactured clinical-grade placenta-derived mesenchymal stem cells (PMSCs) at the UC Davis GMP facility, obtained FDA investigational new drug (IND) approval, and is currently conducting the world’s first stem cell clinical trial using PMSCs for prenatal spina bifida treatment. Additionally, the Wang Lab is advancing non-viral genome editing technologies using lipid nanoparticles to genetically correct developing stem cells, offering a potential prenatal treatment for genetic disorders. To enhance stem cell targeting and function, they have applied novel integrin-based ligands identified through One-Bead One-Compound (OBOC) combinatorial technology. These groundbreaking approaches mark a transformative step in prenatal medicine, with the potential to redefine the management of congenital anomalies.
Biography: Dr. Aijun Wang received his PhD in biology from Tsinghua University, Beijing, China and completed his postdoctoral training at University of California, Berkeley Bioengineering and Berkeley Stem Cell Center. He joined University of California, Davis (UC Davis) faculty in 2012, and is currently a Chancellor's Fellow Professor of Surgery and of Biomedical Engineering. He serves as Vice Chair for Translational Research, Innovation and Entrepreneurship in the Department of Surgery, Co-Director of the Center for Surgical Bioengineering, and inaugural Dean's Fellow in Entrepreneurship at the UC Davis School of Medicine. Additionally, he is a Principal Investigator at the Institute for Pediatric Regenerative Medicine (IPRM) / Shriners Children's Pediatric Research Center, Northern California. Dr. Wang’s research focuses on developing innovative tools, technologies, and therapeutics that integrate molecular, cellular, tissue, and biomaterial engineering to drive tissue regeneration and restore function. Dr. Wang’s lab utilizes single cell spatial multi-omics to study disease mechanisms and developmental process and engineers and develops stem cell therapy/genome editing, extracellular vesicles/nanomedicine, and extracellular matrix/biomaterial scaffolds to treat a wide spectrum of congenital conditions and acquired diseases. Dr. Wang specializes in translating discoveries from bench to bedside through innovative research, translational and investigational new drug (IND)-enabling studies, current Good Manufacturing Practice (cGMP) manufacturing, and clinical trials in both human and companion animal patients. Dr. Wang has published over 180 peer-reviewed papers in top-tier journals, such as Nature Nanotechnology, Nature Communications, ACS Nano, Advanced Functional Materials, Bioactive Materials, Biomaterials, Journal of Extracellular Vesicles, Stem Cells, and Theranostics. Since joining UC Davis, Dr. Wang has served as PI, MPI or Co-PI, on numerous major extramural and intramural grants, securing over $55 million in funding from agencies such as NIH/NINDS, NIH/NIBIB, NIH/NICHD, the California Institute for Regenerative Medicine (CIRM), the Tobacco-Related Disease Research Program of California (TRDRP), Shriners Hospital for Children, and other foundations. Dr. Wang has received numerous awards, such as the UC Davis Health Dean’s Fellowship (2018), the UC Davis Chancellor's Fellowship (2020), the UC Davis Health Dean’s Team Award for Excellence in Research (2020), the UC Davis School of Medicine Cultivating Team Science Award (2022), the KidneyX Innovation award (2020), and the Sacramento Region Innovation Award (2021). In recognition of his outstanding contributions to regenerative medicine and translational bioengineering, Dr. Wang was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2024.
Host: Eunji Chung
Location: Ronald Tutor Hall of Engineering (RTH) - 109
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor. -
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Tue, Mar 11, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Feng Guo, Ph.D., Associate Professor of Intelligent Systems Engineering- Indiana University Bloomington
Talk Title: Brain Organoid computing for Sustainable AI and Medicine
Abstract: The rapid development of artificial intelligence (AI) is transforming our daily lives. However, current silicon-based AI computing devices face growing sustainability challenges. Running generative AI models (e.g., ChatGPT) demands significant computational power, generates excessive heat—requiring substantial cooling resources, and contributes to tremendous carbon emissions. Moreover, the massive manufacturing of silico-based computing chips also costs significant non-renewable sources. To address these issues, neuromorphic devices and systems, inspired by the structure and function of the human brain, are under active development. One promising neuromorphic approach involves utilizing human brain organoids, 3D brain-like tissues derived from pluripotent stem cells. These organoids demonstrate remarkable potential to mimic human brain information processing for sustainable AI and medical applications. However, challenges remain in fully harnessing their capabilities. Our research group has been exploring this new research area—brain organoid computing. In this talk, we will present our latest advancements in developing brain organoid hardware for real-world computing tasks such as speech recognition, equation prediction, and robotic decision-making with unique features including low energy consumption, fast learning, and renewability. Additionally, we will highlight leveraging organoid neural networks for functional phenotyping of neural disorders, including Alzheimer’s disease, reading disorders, substance use disorders, etc. We believe this innovative approach can provide new insights into AI computing, brain-machine interfaces, and translational medicine while fostering a deeper understanding of the synergy between AI and natural intelligence.
Biography: Dr. Feng Guo is an Associated Professor of Intelligent Systems Engineering at Indiana University Bloomington (IUB). Before joining IUB in 2017, he received his Ph.D. in Engineering Science and Mechanics at Penn State and his postdoc training at Stanford University School of Medicine. His group is developing intelligent medical devices, sensors, and systems with the support of multiple NIH and NSF awards. He is a recipient of the NIH Director's New Innovator Award, the Outstanding Junior Faculty Award at IU, Early Career Award at Penn State, the Dean Postdoctoral Fellowship at Stanford School of Medicine, etc.
Host: Qifa Zhou
Location: Michelson Center for Convergent Bioscience (MCB) - 102
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor. -
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Fri, Mar 14, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Sheng Li, Ph. D., Associate Professor in the Department of Cancer Biology at the Keck School of Medicine, University of Southern California. She also serves as the Program Co-Leader of Epigenetic Regulation in Cancer at the USC NCI-designated Norris Comprehensive Cancer Ce
Talk Title: From Aging to Leukemia: Computational Epigenomics of Hematopoietic Stem Cell Fate
Abstract: Aging and epigenetic reprogramming are deeply intertwined in hematopoiesis and leukemogenesis. Our research investigates how genetic and epigenetic alterations shape hematopoietic stem cell (HSC) evolution, clonal expansion, and malignant transformation. First, using our next-generation and long-read sequencing pipelines, we demonstrated that somatic variations in DNA and histone methylation regulators disrupt the DNA methylome, promoting leukemogenesis. Second, we examined how aging alters HSC fate, clonal dynamics, and transcriptional states through genetic barcoding and single-cell RNA sequencing, revealing age-driven shifts in hematopoiesis via in vivo clonal tracing. We also explored how senolytic interventions reshape the aging hematopoietic transcriptome, potentially reversing age-related dysfunction. Finally, clonal hematopoiesis (CH) is an age-associated expansion of mutant hematopoietic stem cells, linked to leukemia and cardiovascular risk. We found that Tet2 deficiency mitigates epigenetic aging, preserving HSC function and assisting clonal expansion. By integrative mining of single-cell RNA sequencing and single-nucleus chromatin accessibility data, we investigated how Tet2 deficiency reprograms the aging epigenome and influences clonal fitness in CH. Together, these findings provide new insights into how aging and epigenetic dysregulation contribute to leukemogenesis and highlight potential therapeutic strategies for mitigating CH and malignant transformation in hematopoietic stem cells.
Biography: Sheng Li, Ph.D., is an Associate Professor in the Department of Cancer Biology at the Keck School of Medicine, University of Southern California. She also serves as the Program Co-Leader of Epigenetic Regulation in Cancer at the USC NCI-designated Norris Comprehensive Cancer Center. Dr. Li received her PhD in Computational Biology from Cornell University in 2014, where she focused on the computational transcriptomics and epigenomics of leukemia relapse. She then served as an Instructor of Bioinformatics at Weill Cornell Medicine in 2014. In 2016, Dr. Li joined the Jackson Laboratory for Genomic Medicine and was promoted to Associate Professor in 2022. In 2024, her lab moved to the USC Keck School of Medicine. The Li lab focuses on algorithm development and integrative mining of long-read, single-cell, and spatial multi-omics data to understand the impact of cell-to-cell variations – in epigenome and transcriptome – and aged microenvironment in driving cancer evolution. The Li Lab has been embedded in a network of NIH consortia, e.g., NCI-NIA jointly funded OncoAging Consortium, NIH Common Fund Cellular Senescence Network (SetNet) Consortium, and NHGRI funded The Encyclopedia of DNA Elements (ENCODE) Consortium. She co-chairs the Omics and Image-Mapping Working Group in SetNet Consortium since 2022. Dr. Li is a recipient of the NIH Maximizing Investigators' Research Award (2019), the American Association for Cancer Research's "NextGen Star" Award (2020), and the Leukemia and Lymphoma Society Scholar (2024).
Host: Peter Wang
Location: Ronald Tutor Hall of Engineering (RTH) - 109
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor. -
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Fri, Mar 14, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Sheng Li, Ph.D., Associate Professor in the Department of Cancer Biology Program Co-Leader of Epigenetic Regulation in Cancer NCI-designated Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California
Talk Title: From Aging to Leukemia: Computational Epigenomics of Hematopoietic Stem Cell Fate
Abstract: Aging and epigenetic reprogramming are deeply intertwined in hematopoiesis and leukemogenesis. Our research investigates how genetic and epigenetic alterations shape hematopoietic stem cell (HSC) evolution, clonal expansion, and malignant transformation. First, using our next-generation and long-read sequencing pipelines, we demonstrated that somatic variations in DNA and histone methylation regulators disrupt the DNA methylome, promoting leukemogenesis. Second, we examined how aging alters HSC fate, clonal dynamics, and transcriptional states through genetic barcoding and single-cell RNA sequencing, revealing age-driven shifts in hematopoiesis via in vivo clonal tracing. We also explored how senolytic interventions reshape the aging hematopoietic transcriptome, potentially reversing age-related dysfunction. Finally, clonal hematopoiesis (CH) is an age-associated expansion of mutant hematopoietic stem cells, linked to leukemia and cardiovascular risk. We found that Tet2 deficiency mitigates epigenetic aging, preserving HSC function and assisting clonal expansion. By integrative mining of single-cell RNA sequencing and single-nucleus chromatin accessibility data, we investigated how Tet2 deficiency reprograms the aging epigenome and influences clonal fitness in CH. Together, these findings provide new insights into how aging and epigenetic dysregulation contribute to leukemogenesis and highlight potential therapeutic strategies for mitigating CH and malignant transformation in hematopoietic stem cells.
Biography: Sheng Li, Ph.D., is an Associate Professor in the Department of Cancer Biology at the Keck School of Medicine, University of Southern California. She also serves as the Program Co-Leader of Epigenetic Regulation in Cancer at the USC NCI-designated Norris Comprehensive Cancer Center. Dr. Li received her PhD in Computational Biology from Cornell University in 2014, where she focused on the computational transcriptomics and epigenomics of leukemia relapse. She then served as an Instructor of Bioinformatics at Weill Cornell Medicine in 2014. In 2016, Dr. Li joined the Jackson Laboratory for Genomic Medicine and was promoted to Associate Professor in 2022. In 2024, her lab moved to the USC Keck School of Medicine. The Li lab focuses on algorithm development and integrative mining of long-read, single-cell, and spatial multi-omics data to understand the impact of cell-to-cell variations – in epigenome and transcriptome – and aged microenvironment in driving cancer evolution. The Li Lab has been embedded in a network of NIH consortia, e.g., NCI-NIA jointly funded OncoAging Consortium, NIH Common Fund Cellular Senescence Network (SetNet) Consortium, and NHGRI funded The Encyclopedia of DNA Elements (ENCODE) Consortium. She co-chairs the Omics and Image-Mapping Working Group in SetNet Consortium since 2022. Dr. Li is a recipient of the NIH Maximizing Investigators' Research Award (2019), the American Association for Cancer Research's "NextGen Star" Award (2020), and the Leukemia and Lymphoma Society Scholar (2024).
Host: Peter Wang
Location: Ronald Tutor Hall of Engineering (RTH) - 109
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor. -
Alfred E.Mann Department of Biomedical Engineering - Seminar series
Fri, Mar 28, 2025 @ 11:00 AM - 12:00 PM
Alfred E. Mann Department of Biomedical Engineering
Conferences, Lectures, & Seminars
Speaker: Ning Wang, Ph.D., Founding Director of Institute for Mechanobiology at Northeastern University, Professor of Bioengineering in Department of Bioengineering in the College of Engineering, affiliate professor at Bouve College of Health Sciences , Northeastern University,
Talk Title: Cytoskeletal Prestress Homeostasis Is A Biological Principle of Living Cells
Abstract: What are the biological principles of living cells is a fundamental question in biology and life sciences. A biological principle is a governing rule that guides structures, functions, and behaviors of living cells. Biological principles are built upon laws of physics and chemistry but go beyond these laws and are unique for living matter. Here we discuss what differentiates a biological principle from a physical principle and discuss candidates for biological principles. We propose the idea of limiting maximum strain on the cell by regulating cytoskeletal prestress (pre-existing tensile stress) and cell modulus (i.e., stiffness). We provide experimental evidence that cytoskeletal prestress homeostasis is a fundamental biological principle of bacteria, single-celled protists, plant cells, and animal cells. We provide strong experimental evidence that regulation of myosin II-mediated cytoskeletal prestress homeostasis is essential for biological structures, functions, and behaviors of animal cells. We reveal that mechanomemory (a biological response long after mechanical perturbations are released) in the cell nucleus is a key in chromatin-stretching dependent rapid gene upregulation. We show evidence that cell softness (the inverse of stiffness) plays a key role in malignant tumor-repopulating cell progression. Leveraging biological principles of the cells (the fire of life-metabolism and the force of life-cytoskeletal prestress homeostasis) may have far-reaching implications in understanding the essence of cell life and designing effective interventions for therapeutics to enhance human health and medicine.
Biography: Professor Ning Wang is the Founding Director of Institute for Mechanobiology at Northeastern University, Professor of Bioengineering in Department of Bioengineering in the College of Engineering, affiliate professor at Bouve College of Health Sciences, Northeastern University. Dr. Wang was the Leonard C and Mary Lou Hoeft Endowed Professor in Engineering from 2014 to 2023 and Professor of Mechanical Science and Engineering from 2006 to 2023 at University of Illinois at Urbana-Champaign. Prior to that, Dr. Wang was on the faculty at Harvard-Chan School of Public Health (HCSPH) from 1994 to 2006 and a research fellow and then a research associate at HCSPH and Harvard Medical School/Children’s Hospital from 1990 to 1994. Dr. Wang received American Physiological Society Scholander Award in 1991 for his contribution to comparative physiology. Wang received Doctor of Science degree in Physiology from Harvard University in 1990 and M.S. in biomedical engineering in 1984 and B.S. in biomechanics in 1982 from Huazhong University of Science and Technology in China.Wang and colleagues invented the Magnetic Twisting Cytometry (MTC) technology for probing a single cell’s mechanical properties and discovered in 1993 that the cell-matrix adhesion molecules-integrins are mechanosensors, spurring the emergence of cellular mechanobiology. Wang and colleagues revealed that E-selectins are mechanosensors in 1996 and E-cadherins are mechanosensors in 2010. Wang lab developed the 3D-MTC that applies mechanical stresses in any direction with varying frequencies in early 2000’s and perfected the technology for anisotropic mechanostimulation, quantification of rheological properties of the cells, and mechanotransduction. He provided first experimental evidence that endogenous cytoskeletal prestress regulates cell shear stiffness and controls gene expression in early 2000’s. Wang’s laboratory discovered stress focusing and the long-distance force propagation in live cells and demonstrated fundamental differences between mechanical force-based signaling and soluble growth factor-based signaling. Professor Wang discovered that an embryonic stem cell differentiates in response to applied forces of physiological magnitudes. Wang’s lab has developed a novel mechanical method that selects and isolates from the general population a small subpopulation of malignant tumor cells (called tumor-repopulating cells) that are highly efficient in metastasis. In recent years Wang’s lab discovered that gene expression can be directly upregulated by stretching the chromatin via applying forces to integrins in a living cell and revealed that the force-induced gene activation depends on histone modifications of the chromatin. Wang lab, working with collaborators, provided experimental evidence that malignant tumor cell softness is critical in cancer malignancy and dormancy. Wang and colleagues developed a rigidified small molecule of synthetic retinoid (a US patent was issued) that efficiently inhibits malignant tumor-repopulating cell metastasis to the lungs in mice models with little toxicity. Wang and colleagues developed a magnetic microrobot probe that can quantify 3D tractions and stiffness in the same location of an embryo or the tumor tissue. Most recently Wang lab revealed chromatin-stretching dependent nuclear basis of mechanomemory (long-term effects after force cessation) in the chromatin and in the nucleoplasm in living cells.
Host: Peter Wang
Location: Ronald Tutor Hall of Engineering (RTH) - 109
Audiences: Everyone Is Invited
Contact: Carla Stanard
This event is open to all eligible individuals. USC Viterbi operates all of its activities consistent with the University's Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor.
